Understanding Restraint of Trade in the Context of IP Licensing

When a pharmaceutical company licenses its patented drug formula to a manufacturer but insists that the manufacturer only buy raw materials from the patent holder’s own subsidiary – is that a legitimate business condition or an anticompetitive stranglehold? This question sits right at the heart of one of the most complex intersections in Indian law: the doctrine of restraint of trade as it applies to intellectual property licensing. IP rights are, by their very nature, monopolies granted by the state to incentivize innovation. But what happens when those monopolies start suppressing the very competition that drives the next wave of innovation? That tension – between protecting IP and preserving market freedom – is what this post explores.

What is restraint of trade in IP licensing? 🔗

The doctrine of restraint of trade originates from contract law. Section 27 of the Indian Contract Act, 1872 declares any agreement that restrains a person from exercising a lawful profession, trade, or business to be void to that extent. While the law recognizes limited exceptions for reasonable restrictions, the fundamental principle is clear: agreements that kill competition are not enforceable.

IP licensing, however, inherently involves some restriction. When a patent holder grants a licence, the licensee is permitted to use the IP only under defined conditions. The licensor naturally wants to protect the commercial value of the IP. The legal challenge is identifying where legitimate protection ends and unlawful restraint begins. In Indian law, this line is drawn through a combination of the Indian Contract Act, IP-specific statutes, and competition law – each adding a distinct layer of scrutiny.

Common restrictive practices in IP licensing agreements 🔗

Certain conditions frequently appear in IP licensing agreements that can cross into restraint of trade territory. Understanding them is essential before understanding how the law responds.

Tie-in arrangements 🔗

A tie-in condition requires a licensee to purchase unrelated products or services exclusively from the licensor as a precondition for obtaining the IP licence. For instance, a patent holder licensing a manufacturing process might insist that the licensee buy all auxiliary components only from the licensor. This restricts the licensee’s freedom to source competitively and can foreclose other suppliers from the market.

Exclusive grant-back provisions 🔗

These clauses require a licensee to assign or exclusively license back to the licensor any improvements or innovations they develop using the licensed IP. While a non-exclusive grant-back may be commercially reasonable, an exclusive grant-back effectively transfers the fruits of the licensee’s own R&D to the licensor, chilling the incentive to innovate and entrenching the licensor’s dominance.

Field-of-use and territorial restrictions 🔗

Field-of-use limitations confine the licensee to using the IP only in specific industries or applications. Territorial restrictions limit where the licensee can operate or sell. While these may serve legitimate market segmentation purposes in some contexts, they can also be used to divide markets in ways that eliminate competition between licensees or between the licensor and licensee in overlapping areas.

Non-compete and no-challenge clauses 🔗

Non-compete clauses prevent licensees from independently developing or commercializing competing technologies. No-challenge clauses bar licensees from contesting the validity of the licensor’s IP. Both are particularly problematic – no-challenge clauses especially so, because they insulate weak or invalid IP from scrutiny, which is against the public interest.

Coercive package licensing 🔗

Also called “block booking,” this practice forces a licensee to take a bundle of IP licences even when they only need one. The licensor conditions access to a desirable patent on accepting licences for other, less valuable or unwanted patents – placing an unjustified financial burden on the licensee and restricting their commercial choices.

The legal framework in India 🔗

India addresses restraint of trade in IP licensing through three overlapping regimes: IP-specific statutory provisions, competition law, and contract law principles applied by courts.

Section 140 of the Patents Act, 1970 🔗

Section 140 of the Patents Act, 1970 is the most direct statutory intervention against restrictive licensing conditions. It declares void any condition in a patent licensing agreement that: forces the licensee to acquire goods exclusively from the licensor; prevents the licensee from using non-patented articles or processes; requires exclusive grant-back; prevents the licensee from challenging the patent’s validity; or imposes coercive package licensing. These conditions are void ab initio – meaning they are treated as never having existed in law, regardless of whether they appear in the main licence agreement or in a separate, ancillary contract.

Crucially, Section 140(3) of the Patents Act provides a defence in infringement proceedings: if a licensee can prove that the contract under which they were operating contained a restrictive condition declared void under Section 140, that itself is a valid defence against an infringement claim. This is a significant procedural protection for licensees.

Section 83 of the Patents Act: general principles of patent working 🔗

Section 83 of the Patents Act sets out the general principles governing how patents should be worked. Section 83(f) explicitly states that patent rights should not be exercised in a way that unreasonably restrains trade or adversely affects the international transfer of technology. This provision directly connects the IP regime to competition principles, making it clear that a patent holder’s right to exploit an invention is not unconditional.

Compulsory licensing under Section 84 🔗

Where a patent holder engages in practices that amount to an abuse of the patent – including through restrictive licensing – Section 84 of the Patents Act provides a mechanism for third parties to apply to the Controller of Patents for a compulsory licence after three years from the date of patent grant. The Controller can grant such a licence if the reasonable requirements of the public are not being met, the patented invention is not available at a reasonably affordable price, or the invention is not being worked in India. The landmark case of Natco Pharma v. Bayer Corporation (2013) – where a compulsory licence was granted for an affordable generic version of the anti-cancer drug Sorafenib – demonstrated that India is willing to deploy this remedy to counter anti-competitive pricing and access restrictions in patent licensing.

Competition law: Section 3 and Section 3(5) of the Competition Act, 2002 🔗

Section 3 of the Competition Act, 2002 prohibits agreements that cause or are likely to cause an Appreciable Adverse Effect on Competition (AAEC) in India. Restrictive terms in IP licensing agreements are assessed as vertical restraints under Section 3(4), which covers tie-in arrangements, exclusive supply and distribution agreements, resale price maintenance, and market restriction. Unlike horizontal agreements (between competitors), which are presumed anticompetitive, vertical restraints like these are assessed using a rule of reason – weighing the pro-competitive justifications against the anticompetitive harm.

The critical carve-out is in Section 3(5), which exempts IP holders from Section 3’s prohibitions to the extent that they are exercising rights conferred under specified IP statutes – the Patents Act, Copyright Act, Trademarks Act, Geographical Indications Act, Designs Act, and Semi-conductor Integrated Circuits Layout-Design Act – or imposing reasonable conditions necessary to protect those rights. This exemption, however, is neither blanket nor unconditional. The Competition Commission of India (CCI) has consistently held that to invoke Section 3(5), the restriction must be both necessary to protect the IP and reasonable – meaning it must be the least restrictive means of asserting the right. In most cases where the carve-out has been claimed, the CCI has found that the conditions imposed were either unnecessary or disproportionate.

It is also important to note that Section 3(5) does not extend to unregistered IP such as trade secrets or unregistered trademarks. Those IP assets receive no exemption from competition scrutiny under this provision.

The rule of reason: how courts and the CCI evaluate restrictions 🔗

Indian courts and the CCI do not treat all restrictive licensing conditions as automatically unlawful. The evaluation is contextual, applying a multi-factor rule of reason analysis:

Necessity: Is the restriction essential to protect the licensor’s legitimate IP interest, or does it go beyond that purpose? A quality control clause in a trademark licence, for instance, may be necessary to protect brand integrity. An obligation to buy unrelated goods from the licensor clearly is not.

Proportionality: Even if the restriction has some justification, is its scope proportionate to the need? A territorial restriction in a narrow geographic market may be acceptable; a global market division clause typically would not be.

Market impact: The CCI is unlikely to find AAEC unless the licensor holds significant market power. Restrictions imposed by a licensor with a minor market share carry less competitive risk than those imposed by a dominant player.

Consumer welfare: Ultimately, do the restrictions harm consumers – through higher prices, reduced choice, or barriers to innovation – or do they promote consumer interests by enabling wider dissemination of the IP?

Key cases shaping the law 🔗

Telefonaktiebolaget LM Ericsson v. Competition Commission of India 🔗

The Ericsson-CCI litigation is the most prominent Indian case at the intersection of IP licensing and competition law. Ericsson, the holder of standard-essential patents (SEPs) for mobile communication technologies, was alleged by Micromax and Intex to have demanded unfair and non-FRAND (Fair, Reasonable and Non-Discriminatory) royalty terms as a condition for licensing. The Delhi High Court confirmed that IP rights do not confer immunity from competition law scrutiny, and the CCI had jurisdiction to examine whether Ericsson’s licensing practices amounted to abuse of dominant position under Section 4 of the Competition Act. This case firmly established that SEP holders, who enjoy market power by virtue of the standardization process, face heightened scrutiny over their licensing terms.

Natco Pharma v. Bayer Corporation 🔗

In this landmark compulsory licensing case, the Controller of Patents granted Natco a compulsory licence to manufacture a generic version of Bayer’s patented cancer drug, Nexavar. The drug was priced at approximately ₹2.8 lakh per month, making it inaccessible to most Indian patients. The decision underscored that patent licensing practices – including pricing and availability conditions – cannot be so restrictive as to deny the public access to life-saving medicines, reinforcing the connection between restraint of trade doctrine and public interest in the IP context.

The balance: IP protection without market foreclosure 🔗

The core challenge for Indian law is calibrating the space between two legitimate interests. IP rights exist to incentivize investment in innovation – without some degree of protection, inventors and companies would have little reason to develop and disclose new technology. But IP rights can also be weaponized to foreclose competition, lock in licensees, and extract supracompetitive rents from markets that depend on the patented technology.

Under Indian law, competition law does not treat IP as inherently hostile to market freedom. Rather, it acts as a corrective mechanism – stepping in when IP holders exceed the scope of the protection their rights were meant to provide. The CCI’s role is not to set fair royalty rates or redesign licensing agreements, but to prevent those agreements from causing appreciable harm to competition. Where restrictions are necessary and proportionate, they are permissible. Where they go further – locking out competitors, suppressing innovation by licensees, or dividing markets – they cross the line into unlawful restraint of trade.

India currently lacks sector-specific technology licensing guidelines or safe harbour provisions (unlike the EU’s Technology Transfer Block Exemption Regulation), which means every licensing dispute requires an individualized assessment. As the CCI matures its jurisprudence in this area, there is a growing call from industry and legal scholars for clearer guidance – particularly in technology-heavy sectors like pharmaceuticals, telecommunications, and software – where IP licensing forms the backbone of commercial relationships.

What do you think? Should India introduce specific safe harbour guidelines for IP licensing agreements – similar to EU’s technology transfer block exemptions – to give businesses greater certainty about where the line between legitimate IP protection and anticompetitive restraint falls? And in sectors like pharmaceuticals, where IP licensing directly affects public health access, should competition authorities play a more proactive role rather than waiting for complaints to be filed?

References

1. https://indiankanoon.org/doc/1306164/
2. https://indiankanoon.org/doc/987101/
3. https://www.lexology.com/library/detail.aspx?g=48237f6b-8ee3-460d-8af3-7b8c26ff7995
4. https://www.azbpartners.com/bank/the-intellectual-property-antitrust-review-india-chapter/
5. https://spicyip.com/2013/03/natco-v-bayer-compulsory-licensing-order.html
6. https://www.indiacode.nic.in/handle/123456789/2010
7. https://www.lakshmisri.com/Media/Uploads/Documents/Interface%20between%20Competition%20Law%20and%20Intellectual%20Property%20Laws%20-%20INDIAN%20PERSPECTIVE.pdf
8. https://www.azbpartners.com/bank/the-intellectual-property-and-antitrust-review-india/
9. https://www.lexology.com/library/detail.aspx?g=f3288edc-c761-425c-9cb7-ec04eb7c3678
10. https://blogs.kcl.ac.uk/kslrcommerciallawblog/2018/07/09/competition-law-intellectual-property-rights-ipr-interface/